A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Allakos Inc.38 sites in 1 country159 target enrollmentDecember 3, 2020

Interventionslirentelimab

Overview

Phase: Phase 3
Intervention: lirentelimab
Conditions: Eosinophilic Gastritis
Sponsor: Allakos Inc.
Enrollment: 159
Locations: 38
Primary Endpoint: The Safety and Tolerability of Lirentelimab by Evaluating Adverse Events Assessed Using the CTCAE Version 5.0
Status: Completed
Last Updated: 2 years ago

This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.

Registry

clinicaltrials.gov

Start Date

December 3, 2020

End Date

July 7, 2023

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Sponsor

Responsible Party

Sponsor

•Provide written informed consent.
•Completed Study AK002-016, defined as having received 6 infusions of study drug and followed through Day 176 (±3) or completed Study AK002-012, defined as having received the cohort-appropriate amount of doses and followed for 5 months after last dose of study drug.
•If patient is on pre-existing dietary restrictions, willingness to maintain those restrictions, throughout the study.
•Able and willing to comply with all study procedures.
•Female patients must be either post-menopausal for at least 1 year or surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity until the end of the study, or for 120 days following the last dose of study drug, whichever is longer.
•Male patients with female partners of childbearing potential must agree to use a highly effective method of contraception until the end of the study or for 120 days following the last dose of study drug, whichever is longer. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant at any time during study participation.

•Known hypersensitivity to any constituent of the study drug.
•Any disease, condition (medical or surgical), or cardiac abnormality, which, in the opinion of the Investigator, would place the patient at increased risk.
•Planned or expected vaccination with live attenuated vaccines during the Treatment Period, or vaccination expected within 5 half-lives (4 months) of AK002 administration.
•Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.
•Any other reason that, in the opinion of the Investigator or Medical Monitor, makes the patient unsuitable for enrollment.